MACROPHAGES/MICROGLIA IN NEURO-INFLAMMATION ASSOCIATED WITH NEURODEGENERATIVE DISEASES
Described herein are methods of treating neuron inflammation conditions, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, ischemic stroke, and prion disease, comprising administering a therapeutically effective amount of cromolyn or a cromolyn derivative compound.
1 . A method of treating a neuron inflammation condition in a patient in need thereof comprising administering to the patient a therapeutically effective amount of at least one compound having the following formula:
provided the compound is not cromolyn disodium,
when the neuron inflammation condition is Alzheimer's Disease (AD).
2 . The method according to claim 1 , wherein the compound has the following formula
3 . The method of claim 1 , wherein the neuron inflammation condition is amyotrophic lateral scerlosis (ALS).
4 . The method of claim 1 , wherein the neuron inflammation condition is AD.
5 . The method of claim 1 , wherein the neuron inflammation is Huntington's Disease.
6 . The method of claim 1 , wherein the neuron inflammation is Parkinson's disease (PD).
7 . The method of claim 1 , wherein the neuron inflammation condition is ischemic stroke.
8 . The method of claim 1 , wherein the neuron inflammation condition is associated with prion disease.
9 - 13 . (canceled)
14 . The method of claim 3 , further comprising co-administering a second compound selected from CD4+; siRNA; miRNA that ameliorates ALS; glial morphology modifier; SOD1 control; and Riluzole.
15 . The method of claim 3 , further comprising co-administering a second compound selected from an anti-aggregation drug and a targeting drug for AD.
16 . The method of claim 1 , wherein the neuron inflammation condition is AD, further comprising co-administering a second compound selected from an antibody targeting drug that ameliorates AD.
17 . The method of claim 1 , wherein the neuron inflammation condition is AD, further comprising co-administering a second compound selected from an anti-inflammatory targeting drug that ameliorates AD.
18 . The method of claim 1 , wherein the neuron inflammation condition is AD, further comprising co-administering a second compound selected from a tau targeting drug that ameliorates AD.
19 . The method of claim 3 , further comprising co-administering a second compound selected from an antibody targeting drug that ameliorates ALS.
20 . The method of claim 3 , further comprising co-administering a second compound selected from an anti-inflammatory targeting drug that ameliorates ALS.
21 . The method of claim 1 , further comprising co-administering a second compound selected from a targeting drug that ameliorates neurodegeneration associated with amyloidosis or tauopathies.
22 . The method of claim 6 , further comprising co-administering a second compound selected from an alpha synuclein targeting drug that ameliorates PD and a Parkinson's targeting drug that ameliorates PD.
23 . The method of claim 3 , wherein the compound is cromolyn disodium.
24 . The method of claim 5 , wherein the compound is cromolyn disodium.
25 . The method of claim 6 , wherein the compound is cromolyn disodium.